Mechanisms of Botulinum Toxin Type A Action on Pain

被引:152
作者
Matak, Ivica [1 ]
Bolcskei, Kata [2 ,3 ]
Bach-Rojecky, Lidija [4 ]
Helyes, Zsuzsanna [2 ,3 ]
机构
[1] Univ Zagreb, Sch Med, Dept Pharmacol, Salata 11, Zagreb 10000, Croatia
[2] Univ Pecs, Sch Med, Dept Pharmacol & Pharmacotherapy, Szigeti Ut 12, H-7624 Pecs, Hungary
[3] Univ Pecs, Ctr Neurosci, Janos Szentagothai Res Ctr, Ifjusag Utja 20, H-7624 Pecs, Hungary
[4] Univ Zagreb, Dept Pharmacol, Fac Pharm & Biochem, Domagojeva 2, Zagreb 10000, Croatia
关键词
botulinum toxin type A; pain therapy; migraine; neuropathic pain; mechanism of action; NEUROTOXIN TYPE-A; MORPHINE ANALGESIC TOLERANCE; DOUBLE-BLIND; CHRONIC MIGRAINE; RAT MODEL; ANTINOCICEPTIVE ACTION; TRIGEMINAL NEURALGIA; NEUROPATHIC PAIN; SENSORY NEURONS; NEUROTRANSMITTER RELEASE;
D O I
10.3390/toxins11080459
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Already a well-established treatment for different autonomic and movement disorders, the use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding. Currently, the only approved use of BoNT/A in relation to pain is the treatment of chronic migraines. However, controlled clinical studies show promising results in neuropathic and other chronic pain disorders. In comparison with other conventional and non-conventional analgesic drugs, the greatest advantages of BoNT/A use are its sustained effect after a single application and its safety. Its efficacy in certain therapy-resistant pain conditions is of special importance. Novel results in recent years has led to a better understanding of its actions, although further experimental and clinical research is warranted. Here, we summarize the effects contributing to these advantageous properties of BoNT/A in pain therapy, specific actions along the nociceptive pathway, consequences of its central activities, the molecular mechanisms of actions in neurons, and general pharmacokinetic parameters.
引用
收藏
页数:24
相关论文
共 152 条
[1]   Analysis of the Mechanisms That Underlie Absorption of Botulinum Toxin by the Inhalation Route [J].
Al-Saleem, Fetweh H. ;
Ancharski, Denise M. ;
Joshi, Suresh G. ;
Elias, M. ;
Singh, Ajay ;
Nasser, Zidoon ;
Simpson, Lance L. .
INFECTION AND IMMUNITY, 2012, 80 (12) :4133-4142
[2]   Identification of the Factors That Govern the Ability of Therapeutic Antibodies to Provide Postchallenge Protection Against Botulinum Toxin: A Model for Assessing Postchallenge Efficacy of Medical Countermeasures against Agents of Bioterrorism and Biological Warfare [J].
Al-Saleem, Fetweh H. ;
Nasser, Zidoon ;
Olson, Rebecca M. ;
Cao, Linsen ;
Simpson, Lance L. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 338 (02) :503-517
[3]   Botulinum Toxin A in Postherpetic Neuralgia A Parallel, Randomized, Double-Blind, Single-Dose, Placebo-controlled Trial [J].
Apalla, Zoe ;
Sotiriou, Elena ;
Lallas, Aimilios ;
Lazaridou, Elizabeth ;
Ioannides, Demetrios .
CLINICAL JOURNAL OF PAIN, 2013, 29 (10) :857-864
[4]   Intra-articular onabotulinumtoxinA in osteoarthritis knee pain: effect on human mechanistic pain biomarkers and clinical pain [J].
Arendt-Nielsen, L. ;
Jiang, G-L ;
DeGryse, R. ;
Turkel, C. C. .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2017, 46 (04) :303-316
[5]   Botulinum toxin as a biological weapon - Medical and public health management [J].
Arnon, SS ;
Schechter, R ;
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Fine, AD ;
Hauer, J ;
Layton, M ;
Lillibridge, S ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Swerdlow, DL ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (08) :1059-1070
[6]   Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial [J].
Attal, Nadine ;
de Andrade, Daniel C. ;
Adam, Frederic ;
Ranoux, Daniele ;
Teixeira, Manoel J. ;
Galhardoni, Ricardo ;
Raicher, Irina ;
Ueceyler, Nurcan ;
Sommer, Claudia ;
Bouhassira, Didier .
LANCET NEUROLOGY, 2016, 15 (06) :555-565
[7]   Botulinum toxin type A in experimental neuropathic pain [J].
Bach-Rojecky, L ;
Relja, M ;
Lackovic, Z .
JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (02) :215-219
[8]   Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation [J].
Bach-Rojecky, Lidija ;
Dominis, Mara ;
Lackovic, Zdravko .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 (05) :503-509
[9]   Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection [J].
Bach-Rojecky, Lidija ;
Salkovic-Petrisic, Melita ;
Lackovic, Zdravko .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 633 (1-3) :10-14
[10]   Central origin of the antinociceptive action of botulinum toxin type A [J].
Bach-Rojecky, Lidija ;
Lackovic, Zdravko .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2009, 94 (02) :234-238